Vyvanse is a stimulant medication belonging to the amphetamine class [1]. It is specifically classified as a central nervous system (CNS) stimulant [2].
What is the active ingredient in Vyvanse?
The active ingredient in Vyvanse is lisdexamfetamine dimesylate [3]. This is a prodrug, meaning it is converted into dextroamphetamine, the active form, after ingestion [4].
How does lisdexamfetamine work?
Lisdexamfetamine dimesylate is designed to be slowly absorbed and metabolized in the body [4]. Once it reaches the bloodstream, it is hydrolyzed into dextroamphetamine, which increases the levels of dopamine and norepinephrine in the brain [5]. These neurotransmitters are crucial for attention and impulse control [5].
What conditions is Vyvanse prescribed for?
Vyvanse is approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children aged six years and older [3]. It is also indicated for the treatment of moderate to severe binge-eating disorder (BED) in adults [3].
How does Vyvanse compare to other ADHD medications?
As a stimulant, Vyvanse functions similarly to other amphetamine-based medications used for ADHD, such as Adderall (amphetamine and dextroamphetamine salts) [6]. However, Vyvanse's prodrug formulation is designed for a smoother, more sustained release of the active compound, potentially leading to less pronounced peaks and troughs compared to immediate-release stimulants [4][7]. Non-stimulant ADHD medications, like atomoxetine, work through different mechanisms and are an alternative for patients who cannot tolerate or do not respond well to stimulants [8].
When does the patent for Vyvanse expire?
The primary patents protecting Vyvanse (lisdexamfetamine dimesylate) began expiring around 2023 [9]. However, the exact expiry dates can be complex due to various secondary patents, including those related to manufacturing processes, formulations, and methods of use, which may extend market exclusivity for certain aspects of the drug [10].
What are the risks associated with Vyvanse?
Vyvanse carries risks, including potential for misuse, abuse, and dependence [3]. It can also cause serious cardiovascular problems, including sudden death in individuals with pre-existing heart conditions [3]. Other potential side effects include psychiatric problems, such as hallucinations or manic episodes, and slowed growth in children [3].
Can generic versions of Vyvanse be manufactured?
With the expiration of key patents, generic versions of lisdexamfetamine dimesylate have become available. The introduction of generics typically leads to lower prices for the medication [11].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/vyvanse
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021743s024,022963s007lbl.pdf
[4] https://www.drugpatentwatch.com/news/vyvanse-patent-litigation-and-generic-entry-analysis
[5] https://pubmed.ncbi.nlm.nih.gov/20462403/
[6] https://www.drugpatentwatch.com/drug/adderall
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197601/
[8] https://www.drugpatentwatch.com/drug/strattera
[9] https://www.drugpatentwatch.com/drug/lisdexamfetamine-dimesylate
[10] https://www.drugpatentwatch.com/blog/understanding-patent-cliff
[11] https://www.drugpatentwatch.com/blog/the-impact-of-generic-entry-on-drug-pricing